Packages (Simulation)
Reagent Preparation
        Image (I)
Image (II)
Certificate
    
Multiplex Assay Kit for Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) ,etc. by FLIA (Flow Luminescence Immunoassay)
(Note: Up to 8-plex in one testing reaction)
- Product No.LMB934Hu
 - Organism SpeciesHomo sapiens (Human) Same name, Different species.
 - Sample TypeSerum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
 - Test MethodDouble-antibody Sandwich
 - Assay Length3.5h
 - Detection Range0.2-200ng/mL
 - SensitivityThe minimum detectable dose of this kit is typically less than 0.067 ng/mL.
 - DownloadInstruction Manual
 - UOM 8Plex 7Plex 6Plex 5Plex 4Plex 3Plex 2Plex1Plex
 - FOB
    
                                    US$ 415 
                                        US$ 431 
                                        US$ 455 
                                        US$ 487 
                                        US$ 519 
                                        US$ 567 
                                        US$ 638 
            
                
                        US$ 798 
                    
            Add to Price Calculator
            
            Result        
For more details, please contact local distributors! 
Specificity
                        This assay has high sensitivity and excellent specificity for detection of Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) ,etc. by FLIA (Flow Luminescence Immunoassay).
                        No significant cross-reactivity or interference between Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.
                    
Recovery
Matrices listed below were spiked with certain level of recombinant Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
| Matrix | Recovery range (%) | Average(%) | 
| serum(n=5) | 81-104 | 90 | 
| EDTA plasma(n=5) | 92-99 | 95 | 
| heparin plasma(n=5) | 85-99 | 89 | 
Precision
                    Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively. 
                    Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate. 
                    CV(%) = SD/meanX100 
                    Intra-Assay: CV<10% 
                    Inter-Assay: CV<12% 
                
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 | 
| serum(n=5) | 98-105% | 88-102% | 84-93% | 79-102% | 
| EDTA plasma(n=5) | 97-105% | 83-97% | 81-89% | 78-98% | 
| heparin plasma(n=5) | 89-98% | 88-98% | 91-103% | 78-96% | 
Stability
                    The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. 
                    To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
                
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity | 
| 96-well plate | 1 | Plate sealer for 96 wells | 4 | 
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL | 
| Pre-Mixed Magnetic beads (22#:LRG1) | 1 | Analysis buffer | 1×20mL | 
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL | 
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL | 
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL | 
| Instruction manual | 1 | 
Assay procedure summary
                    1. Preparation of standards, reagents and samples before the experiment;
                            2. Add 100μL standard or sample to each well, 
                                add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
                            3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
                            4. Wash plate on magnetic frame for three times;
                            5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
                            6. Wash plate on magnetic frame for three times;
                            7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
                
GIVEAWAYS
INCREMENT SERVICES
| Magazine | Citations | 
| Clin Exp Nephrol | Differentially expressed urinary biomarkers in children with idiopathic nephrotic syndrome PubMed: 26351173 | 
| Journal of Proteome Research | Targeted proteomics predict a sustained complete-response after transarterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma: a prospective cohort study pubmed:28112944 | 
| OncoTargets and Therapy | leucine-rich alpha-2-glycoprotein-1 is up-regulated in colorectal cancer and is a tumor promoter Pubmed:29785123 | 
| PROTEOMICS – Clinical Applications | Screening and Identification of Pregnancy Zone Protein (PZP) and Leucine‐Rich Alpha‐2‐Glycoprotein (LRG) as Potential Serum Biomarkers for Early‐onset … Pubmed: 30411527 | 
| Cancer Management and Research | iTRAQ-based quantitative protein expression profiling of biomarkers in childhood B-cell and T-cell acute lymphoblastic leukemia Pubmed: 31440093 | 
| J Clin Med | A Three-Protein Panel to Support the Diagnosis of Sepsis in Children Pubmed:35329889 | 
        
                                    
                            
